BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Ipsen 

39, rue du Bois Chaland

Evry Cedex    91029  France
Phone: 33-1-608-72600 Fax: 33-1-608-61609


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical






 Company News
New England Journal Of Medicine Publishes Ipsen (IPN.PA)’s Somatuline® CLARINET® Phase III Results In Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors 7/17/2014 10:59:14 AM
Ipsen (IPN.PA) And Galderma Laboratories Become Exclusive Partners For Development And Marketing Of Neurotoxins In The US, Canada, Brazil And Europe 7/11/2014 9:08:57 AM
Ipsen (IPN.PA) Submits Marketing Authorization Applications In The U.S. And Europe For Somatuline® (Lanreotide) In The Treatment Of Gastroenteropancreatic Neuroendocrine Tumors (GEP-Nets) 7/1/2014 10:36:58 AM
Ipsen (IPN.PA) Joins PHARNEXT's Board Of Directors 6/30/2014 9:23:00 AM
Ipsen (IPN.PA) Announces A Step Forward In The Resupply Of Increlex® (Mecasermin [rDNA Origin] Injection) In The U.S. 5/13/2014 8:27:21 AM
Ipsen (IPN.PA) Announces Name Change For Its Research And Development Affiliate In The U.S. From Biomeasure, Inc. To Ipsen Bioscience, Inc. 5/6/2014 10:18:39 AM
Ipsen (IPN.PA)’s First Quarter 2014 Sales 4/30/2014 8:14:37 AM
Ipsen (IPN.PA) Announces A First Set Of Results On Positive Phase III Clinical Study Of Dysport® In The Treatment Of Adults Suffering From Upper Limb Spasticity At The 8th World Congress For Neurorehabilitation In Istanbul 4/14/2014 9:38:54 AM
Ipsen (IPN.PA) Eligible For PEA-PME And Included In CAC® PME Index By Euronext 4/9/2014 9:31:49 AM
Ipsen (IPN.PA): Dysport Incontinence Treatment Phase 2a Trial Positive 3/18/2014 7:06:30 AM
12345678910...